|
1
|
Nilsen TW and Graveley BR: Expansion of
the eukaryotic proteome by alternative splicing. Nature.
463:457–463. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang ET, Sandberg R, Luo S, Khrebtukova I,
Zhang L, Mayr C, Kingsmore SF, Schroth GP and Burge CB: Alternative
isoform regulation in human tissue transcriptomes. Nature.
456:470–476. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pan Q, Shai O, Lee LJ, Frey BJ and
Blencowe BJ: Deep surveying of alternative splicing complexity in
the human transcriptome by high-throughput sequencing. Nat Genet.
40:1413–1415. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Venables JP: Aberrant and alternative
splicing in cancer. Cancer Res. 64:7647–7654. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim E, Goren A and Ast G: Insights into
the connection between cancer and alternative splicing. Trends
Genet. 24:7–10. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oltean S and Bates DO: Hallmarks of
alternative splicing in cancer. Oncogene. 33:5311–5318. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu S and Cheng C: Alternative RNA
splicing and cancer. Wiley Interdiscip Rev RNA. 4:547–566. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Warzecha CC, Jiang P, Amirikian K, Dittmar
KA, Lu H, Shen S, Guo W, Xing Y and Carstens RP: An ESRP-regulated
splicing programme is abrogated during the epithelial-mesenchymal
transition. EMBO J. 29:3286–3300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hudler P: Genetic aspects of gastric
cancer instability. Sci World J. 2012:7619092012. View Article : Google Scholar
|
|
12
|
Tao J, Deng NT, Ramnarayanan K, Huang B,
Oh HK, Leong SH, Lim SS, Tan IB, Ooi CH, Wu J, et al: CD44-SLC1A2
gene fusions in gastric cancer. Sci Transl Med. 3:77ra302011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zouridis H, Deng N, Ivanova T, Zhu Y, Wong
B, Huang D, Wu YH, Wu Y, Tan IB, Liem N, et al: Methylation
subtypes and large-scale epigenetic alterations in gastric cancer.
Sci Transl Med. 4:156ra1402012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Calcagno DQ, Gigek CO, Chen ES, Burbano RR
and Smith MA: DNA and histone methylation in gastric
carcinogenesis. World J Gastroenterol. 19:1182–1192. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu WK, Lee CW, Cho CH, Fan D, Wu K, Yu J
and Sung JJ: MicroRNA dysregulation in gastric cancer: A new player
enters the game. Oncogene. 29:5761–5771. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li T, Mo X, Fu L, Xiao B and Guo J:
Molecular mechanisms of long noncoding RNAs on gastric cancer.
Oncotarget. 7:8601–8612. 2016.PubMed/NCBI
|
|
17
|
Ludwig JA and Weinstein JN: Biomarkers in
cancer staging, prognosis and treatment selection. Nat Rev Cancer.
5:845–856. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yuan Y, Van Allen EM, Omberg L, Wagle N,
Amin-Mansour A, Sokolov A, Byers LA, Xu Y, Hess KR, Diao L, et al:
Assessing the clinical utility of cancer genomic and proteomic data
across tumor types. Nat Biotechnol. 32:644–652. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li XW, Shi BY, Yang QL, Wu J, Wu HM, Wang
YF, Wu ZJ, Fan YM and Wang YP: Epigenetic regulation of CDH1 exon 8
alternative splicing in gastric cancer. BMC Cancer. 15:9542015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hafezi N, Ajami A, Farazmandfar T,
Hosseini V, Alizadeh-Navaei R and Tehrani M: Increased expression
of two alternative spliced variants of CD1d molecule in human
gastric cancer. Iran J Immunol. 12:129–140. 2015.PubMed/NCBI
|
|
21
|
Tsai YS, Dominguez D, Gomez SM and Wang Z:
Transcriptome-wide identification and study of cancer-specific
splicing events across multiple tumors. Oncotarget. 6:6825–6839.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Armero VE, Tremblay MP, Allaire A,
Boudreault S, Martenon-Brodeur C, Duval C, Durand M, Lapointe E,
Thibault P, Tremblay-Létourneau M, et al: Transcriptome-wide
analysis of alternative RNA splicing events in Epstein-Barr
virus-associated gastric carcinomas. PLoS One. 12:e01768802017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Uozaki H and Fukayama M: Epstein-Barr
virus and gastric carcinoma - viral carcinogenesis through
epigenetic mechanisms. Int J Clin Exp Pathol. 1:198–216.
2008.PubMed/NCBI
|
|
24
|
Ryan M, Wong WC, Brown R, Akbani R, Su X,
Broom B, Melott J and Weinstein J: TCGASpliceSeq a compendium of
alternative mRNA splicing in cancer. Nucleic Acids Res.
44:D1018–D1022. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ryan MC, Cleland J, Kim R, Wong WC and
Weinstein JN: SpliceSeq: A resource for analysis and visualization
of RNA-Seq data on alternative splicing and its functional impacts.
Bioinformatics. 28:2385–2387. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lex A, Gehlenborg N, Strobelt H, Vuillemot
R and Pfister H: UpSet: Visualization of intersecting sets. IEEE
Trans Vis Comput Graph. 20:1983–1992. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM classification of malignant tumours. 7th edition.
Wiley-Blackwell; Oxford: pp. 3102009
|
|
28
|
Brown RL, Reinke LM, Damerow MS, Perez D,
Chodosh LA, Yang J and Cheng C: CD44 splice isoform switching in
human and mouse epithelium is essential for epithelial-mesenchymal
transition and breast cancer progression. J Clin Invest.
121:1064–1074. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang L, Deng J, Zhu X, Zheng J, You Y, Li
N, Wu H, Lu J and Zhou Y: CD44 rs13347 C>T polymorphism predicts
breast cancer risk and prognosis in Chinese populations. Breast
Cancer Res. 14:R1052012. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu XM, Yang HG, Zheng BA, Cao HF, Hu ZM
and Wu WD: Functional genetic variations at the microRNA
binding-site in the CD44 gene are associated with risk of
colorectal cancer in Chinese populations. PLoS One.
10:e01275572015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Suenaga M, Yamada S, Fuchs BC, Fujii T,
Kanda M, Tanaka C, Kobayashi D, Fujiwara M, Tanabe KK and Kodera Y:
CD44 single nucleotide polymorphism and isoform switching may
predict gastric cancer recurrence. J Surg Oncol. 112:622–628. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sharma S and Lichtenstein A: Aberrant
splicing of the E-cadherin transcript is a novel mechanism of gene
silencing in chronic lymphocytic leukemia cells. Blood.
114:4179–4185. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sharma S, Liao W, Zhou X, Wong DT and
Lichtenstein A: Exon 11 skipping of E-cadherin RNA downregulates
its expression in head and neck cancer cells. Mol Cancer Ther.
10:1751–1759. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li X, Gao Y, Pan Y, Pan Y, Wang L, Xiao N,
He Q, Fan Y and Wang Y: Mutation screen and RNA analysis disclose
the changed splicing of the E-cadherin transcription in gastric
cancer. Fam Cancer. 12:547–554. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ruvinsky I and Meyuhas O: Ribosomal
protein S6 phosphorylation: From protein synthesis to cell size.
Trends Biochem Sci. 31:342–348. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim SH, Jang YH, Chau GC, Pyo S and Um SH:
Prognostic significance and function of phosphorylated ribosomal
protein S6 in esophageal squamous cell carcinoma. Mod Pathol.
26:327–335. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen B, Tan Z, Gao J, Wu W, Liu L, Jin W,
Cao Y, Zhao S, Zhang W, Qiu Z, et al: Hyperphosphorylation of
ribosomal protein S6 predicts unfavorable clinical survival in
non-small cell lung cancer. J Exp Clin Cancer Res. 34:1262015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Akar U, Ozpolat B, Mehta K,
Lopez-Berestein G, Zhang D, Ueno NT, Hortobagyi GN and Arun B:
Targeting p70S6K prevented lung metastasis in a breast cancer
xenograft model. Mol Cancer Ther. 9:1180–1187. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pagano M: Cell cycle regulation by the
ubiquitin pathway. FASEB J. 11:1067–1075. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xie C, Powell C, Yao M, Wu J and Dong Q:
Ubiquitin-conjugating enzyme E2C: A potential cancer biomarker. Int
J Biochem Cell Biol. 47:113–117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee SW, Han SI, Kim HH and Lee ZH:
TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by
receptor activator of NF-kappaB. J Biochem Mol Biol. 35:371–376.
2002.PubMed/NCBI
|
|
43
|
Yamaguchi T, Miyashita C, Koyano S, Kanda
H, Yoshioka K, Shiba T, Takamatsu N and Ito M: JNK-binding protein
1 regulates NF-kappaB activation through TRAF2 and TAK1. Cell Biol
Int. 33:364–368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fu L, Shi J, Hu K, Wang J, Wang W and Ke
X: Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is
an unfavorable prognostic biomarker in cytogenetically normal acute
myeloid leukemia. Oncotarget. 6:8144–8154. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Matera AG and Wang Z: A day in the life of
the spliceosome. Nat Rev Mol Cell Biol. 15:108–121. 2014.
View Article : Google Scholar :
|
|
46
|
Matlin AJ, Clark F and Smith CW:
Understanding alternative splicing: Towards a cellular code. Nat
Rev Mol Cell Biol. 6:386–398. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Naftelberg S, Schor IE, Ast G and
Kornblihtt AR: Regulation of alternative splicing through coupling
with transcription and chromatin structure. Annu Rev Biochem.
84:165–198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Alló M, Buggiano V, Fededa JP, Petrillo E,
Schor I, de la Mata M, Agirre E, Plass M, Eyras E, Elela SA, et al:
Control of alternative splicing through siRNA-mediated
transcriptional gene silencing. Nat Struct Mol Biol. 16:717–724.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Makeyev EV, Zhang J, Carrasco MA and
Maniatis T: The MicroRNA miR-124 promotes neuronal differentiation
by triggering brain-specific alternative pre-mRNA splicing. Mol
Cell. 27:435–448. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shukla S, Kavak E, Gregory M, Imashimizu
M, Shutinoski B, Kashlev M, Oberdoerffer P, Sandberg R and
Oberdoerffer S: CTCF-promoted RNA polymerase II pausing links DNA
methylation to splicing. Nature. 479:74–79. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Danan-Gotthold M, Golan-Gerstl R,
Eisenberg E, Meir K, Karni R and Levanon EY: Identification of
recurrent regulated alternative splicing events across human solid
tumors. Nucleic Acids Res. 43:5130–5144. 2015. View Article : Google Scholar : PubMed/NCBI
|
